Market Intelligence, Clinical Progress, and High-Purity Reagents for Lipid Metabolism, Drug-Induced Phospholipidosis, Metabolic Disease, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for LYPLA3/PLA2G15 drug discovery, toxicity screening, and mechanism studies. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LYPLA3/PLA2G15 Recombinant Protein (Wild-Type & Catalytic Mutant). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 expressed (native glycosylation) preserves structural integrity and activity in acidic buffers. Includes active site mutants (S/A, D/A, H/A) for mechanism studies. | View LYPLA3 Products |
| Gene Delivery | LYPLA3/PLA2G15 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines in HEK293. CMV or EF1a promoter options. | View LYPLA3 Products |
| Benchmark Ab | Anti-LYPLA3/PLA2G15 (Biosimilar Sequence). Recombinant positive control for cellular assays. | View LYPLA3 Products |
| Validator | LYPLA3/PLA2G15 siRNA Set (3 unique sequences). For specific knockdown verification in lipid storage models and specificity controls. | View LYPLA3 Products |
| Isoform Panel | PLA2 Family Selectivity Panel (PLA2G1B, PLA2G2A, PLA2G4A, PLA2G7, LYPLA3). Matched purity standards (>95% by mass spec) for cross-reactivity screening. | View PLA2G7 Products |
| Related Target A | CD1D. Lipid antigen presentation partner interacting directly with LPLA2 pathways. | View CD1D Products |
| Related Target B | SMPD1. Acid sphingomyelinase; synergistic lysosomal target in metabolic phenotyping. | View SMPD1 Products |
| Related Target C | PNPLA3 (I148M Mutant Protein). Competing pathway in hepatic lipid metabolism; frequent comorbidity target. | View PNPLA3 Products |
| Related Target D | LPAR1 (Overexpression Lysate). Downstream signaling validation; LYPLA3 regulates LPA precursor levels. | View LPAR1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Lysosomal Enzyme Stability (Low pH Assays) | HEK293 Expressed (Native Glycosylation) preserves structural integrity and activity in acidic buffers (pH 4.5-5.0). |
| Homolog Counter-Screening (PLA2 Family) | Strictly sequence-verified homolog panel proteins ensuring high selectivity in High-Throughput Screening (HTS). |
| Lack of Reliable Assay Controls | Recombinant positive control antibodies and high-purity WT proteins available off-the-shelf or via custom virtual inventory. |
| Toxicity Model Validation (False Positives) | Validated siRNA included for background specificity checks in drug-induced phospholipidosis (DIPL) screens. |
| Isoform Selectivity (vs PLA2G1B/G2A/G4A) | Homologous PLA2 Panel proteins strictly verified by mass spec (>95% purity); matched enzymatic activity units. |
| Catalytic Mechanism Validation | Active Site Mutants (Ser/Asp/His → Ala) available; Sequence Verified for mechanism of action studies. |
| Cross-species Preclinical Translation | Human/Mouse/Rat ortholog proteins available with >95% purity; endotoxin controlled. |
| Cell-based Target Engagement | Lentivirus for stable overexpression; HEK293 expressed for native folding. |
Live LYPLA3/PLA2G15 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (PLA2G15)
- ➤ View Active Clinical Trials (LYPLA3)
- ➤ Latest Resistance & Toxicity Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
LYPLA3/PLA2G15 (Lysosomal Phospholipase A2 or LPLA2) plays a highly specialized dual role in pharmaceutical R&D. Primarily, it acts as a critical anti-target in drug safety screening: cationic amphiphilic drugs (CADs) frequently inhibit LPLA2, leading to Drug-Induced Phospholipidosis (DIPL). As regulatory agencies demand stricter early-stage toxicity profiling, robust high-throughput LPLA2 enzymatic assays are in high demand. Concurrently, the therapeutic race is intensifying with major players shifting from broad-spectrum PLA2 inhibitors to isoform-selective small molecules targeting LYPLA3 for metabolic diseases (obesity, NAFLD, insulin resistance), autoimmune disorders, and oncology indications (tumor microenvironment lipid reprogramming). Next-wave R&D focuses on optimizing chemical series to avoid LYPLA3 binding (toxicity screens) or to selectively modulate its activity, often in combination with statins or GLP-1 agonists.
Competitive Modality & Indication Snapshot
| Modality | Representative Focus / Players | Key Indications / Uses | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Inhibitor) | Metabolic R&D Biotech; Novartis, Eli Lilly | Autoimmune, Atherosclerosis, Obesity, Type 2 Diabetes, NAFLD | High-Throughput Enzymatic Screening (Need High-Purity HEK293 Proteins and PLA2 isoform panel) |
| Toxicity Counterscreen (CADs) | Global Big Pharma (Safety/Tox) | Drug-Induced Phospholipidosis (DIPL) | Selectivity Assay (Need precisely folded enzyme active at low pH and DIPL-specific siRNA controls) |
| Targeted Protein Degraders (PROTAC) | Emerging PROTAC pipelines; Undisclosed programs | Tumor Microenvironment (Lipid), Refractory Metabolic Disease | Intracellular Degradation (Need siRNA, specific anti-target Abs, and lentivirus stable lines) |
| Covalent Inhibitor | Academic consortia (UCLA, Michigan) | Insulin Resistance | Active Site Mutant Controls (Need catalytic triad mutants for mechanism validation) |
| Antibody/Peptide Blocker | Emerging biotechs | Solid Tumors (metastasis) | High-concentration Stability (Need >95% pure antigen for binding assays) |